Cohance Lifesciences Receives FDA 483 With Five Observations For Hyderabad Facility

Market snapshot: Cohance Lifesciences has received a Form FDA 483 with five observations following a USFDA inspection of its Pashamylaram, Hyderabad facility. At the same time, unverified source reports claim a year-on-year revenue contraction and continued consolidated net losses for the quarter ended June 30, 2026.

Data Snapshot

• USFDA completed inspection of the Pashamylaram facility from July 27 to August 5, 2026, issuing 5 observations with no data integrity issues highlighted.
• Consolidated revenue from operations for the full financial year ended March 31, 2026, stood at ₹2,269 crore.
• Consolidated revenue from operations in Q4 FY26 was reported at ₹619 crore, with Adjusted EBITDA standing at ₹130 crore.

What's Changed

• Pashamylaram regulatory status shifted with five fresh USFDA observations on Form 483, following a zero-observation USFDA clearance at the Jaggaiahpet API facility on August 4, 2026.
• The leadership structure is in transition with former Cipla CEO Umang Vohra actively heading the executive team as Group CEO, while CFO Himanshu Agarwal's resignation is set to take effect on September 13, 2026.

Key Takeaways

• Pashamylaram facility receives 5 USFDA observations on Form 483, though management clarified that none are linked to data integrity issues.
• Q1 revenue is reportedly ₹422 crore (as stated in the source alert; not independently verified), marking a decline from ₹550 crore YoY (as stated in the source alert; not independently verified).
• Q1 consolidated net loss narrows reportedly to ₹24.1 crore from ₹48.9 crore YoY (as stated in the source alert; not independently verified).
• Management previously guided that Q1 FY27 would represent the low point for revenues and margins before recovery in the second half of the fiscal year.

SAHI Perspective

The five observations at Pashamylaram present a near-term compliance hurdle, but are manageable given the lack of data integrity issues and the positive precedent set by the zero-observation audit at the Jaggaiahpet plant. Operationally, the unverified revenue numbers indicate that the business is going through the trough phase guided by management in May, as shipments are heavily back-ended towards the second half of the year.

Market Implications

Short-term pressure on the stock is likely due to the regulatory overhang at a key CDMO facility, especially as previous disruptions at the Nacharam facility historical dragged down overall FY26 metrics. However, stock sentiment will likely stabilize once the corrective and preventive action (CAPA) plan is formally accepted by the USFDA and shipment recovery begins in 2H FY27.

Trading Signals

Market Bias: Bearish

The near-term bias is bearish due to the regulatory overhang of five observations at the Pashamylaram facility, coupled with unverified Q1 results indicating a significant year-on-year revenue contraction.

Underweight: Pharmaceuticals & Biotechnology

Trigger Factors:

• Timely submission and USFDA acceptance of CAPAs for the Pashamylaram facility.
• Signs of volume recovery and shipment normalization in the 2H FY27 results.
• Seamless transition of the executive leadership team following the CFO's exit in September.

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian pharmaceutical CDMO industry has faced challenging destocking cycles and cost pressures. Companies are increasingly investing in specialty platforms like ADCs and oligonucleotides to move up the value chain. Under its new management team, Cohance is positioning itself as a technology-led global CDMO, though near-term regulatory clearances remain essential to maintain customer pipeline trust.

Key Risks to Watch

• Risk of the Pashamylaram observations escalating to a Warning Letter or Official Action Indicated (OAI) status.
• Failure to resolve the USFDA observations within the expected corrective action timelines.
• Delay in customer conversions and commercial scaling of key molecules in the second half of the fiscal year.

Recent Developments

On August 4, 2026, Cohance Lifesciences cleared a general USFDA GMP audit of its Jaggaiahpet API manufacturing facility with zero observations. Additionally, on June 16, 2026, promoters Berhyanda Limited and Jusmiral Holdings released encumbrance over 57.49% of the total share capital. Whole-time Director and CFO Himanshu Agarwal has resigned, effective September 13, 2026.

Closing Insight

While the regulatory observations at Pashamylaram demand operational focus, they do not block long-term growth prospects given the clean sheet at Jaggaiahpet. With new CEO Umang Vohra guiding the high-potent API and specialty platforms, the company remains structurally sound despite a seasonally weak and regulatory-heavy first half.

High Performance Trading with SAHI.